Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated with H. pylori Infection and Gastric Cancer Carcinogenesis

This clinical trial is for non-gender specific adults ages 18-100 years old with H.pylori infection.
   
The purpose of this study is to learn how the H.pylori infection can lead to cancer as well as provide information on possible intervention treatments that can be administered prior to the development of advanced cancer.
   

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

This is an observational study for people with myelofibrosis (MF), lower risk or higher risk myelodysplastic syndromes (MDS), Idiopathic Cytopenia of Undetermined Significance (ICUS), and acute myeloid leukemia (AML).

Comparison of Venipuncture Serum Prostate Specific Antigen (PSA) with Point of Care Fingerstick Blood Draw Rapid Test for PSA (RT-PSA)

The clinical trial is for men, with or without a diagnosis of prostate cancer, who are about to undergo a routine prostate-specific antigen (PSA) test.
   
The purpose of this study is to see if a PSA value derived from the Point of Care Rapid Test for is similar to the value obtained from a certified laboratory. 
   
Participants who are visiting their physician to have their blood drawn to measure a PSA value will, within 1 hour of the blood test, also have a finger stick blood draw with a drop of blood placed on the measurement strip. 

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

This is a clinical trial for adults who have been diagnosed with Melanoma or Non-Small Cell Lung Cancer (NSCLC).

The purpose of this study is to test the safety and efficacy of an investigational drug RP1 when it is injected into a tumor on its own as well as in combination with nivolumab for the treatment of certain types of solid tumors. 

Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

This is a clinical trial for adult men with progressive metastatic castration resistant prostate cancer.
   
The purpose of the initial phase I portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 plus 177Lu-PSMA-I&T that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 plus 177Lu-PSMA-I&T leads to treatment response. 
   

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

This is a clinical trial for adult men diagnosed with progressive metastatic castration-resistant prostate cancer. 
   
The main purpose of this study is to evaluate the maximum tolerated and recommended dose of pembrolizumab and an androgen-receptor pathway inhibitor with or without the investigational drug 225Ac-J591 to see what its side effects are and if it works for this type of cancer.

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma

This is a clinical trial for adults with metastatic squamous cell carcinoma of the esophagus.
   
The purpose of this study is to test two treatment regimens in people with advanced esophageal cancer to see how well they work to stop the cancer as well as to determine whether one treatment regimen is more effective than the other. The two treatment regimens being evaluated are lenvatinib + pembrolizumab with chemotherapy followed by lenvatinib + pembrolizumab compared to pembrolizumab with chemotherapy.
   

Liver Cirrhosis Network Cohort Study

This is a study for women and men who are 18 years old and above and have been diagnosed with cirrhosis (scarring of the liver). This study is being conducted to identify things that contribute to keeping people healthy when they are living with liver cirrhosis.